Hepatocellular Carcinoma

Tivantinib Improves Survival in HCC Patients

(ChemotherapyAdvisor) – Tivantinib increases time to tumor progression (TTP) and survival in patients with Met-positive hepatocellular carcinoma (HCC), according to the results of a phase 2 study presented at the 2012 Association for Clinical Oncology. The abstract was entitled “Tivantinib (ARQ 197) versus placebo in patients (Pts) with hepatocellular carcinoma (HCC) who failed one systemic…

Next post in Fact Sheets